To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of darbepoetin alfa.
DATA SOURCES:
Pertinent references were identified by a MEDLINE search (1995–January 2001) of the medical literature, review of English-language literature and references of these articles, product information, and abstracts from professional meetings.
STUDY SELECTION:
Clinical efficacy data were gathered from all available trial data citing darbepoetin alfa. Additional information concerning pharmacology, pharmacokinetics, and safety was also reviewed.
DATA SYNTHESIS:
Darbepoetin alfa is a new erythropoiesis-stimulating protein with a threefold longer half-life than recombinant human erythropoietin (r-HuEPO). Darbepoetin alfa is approved for intravenous and subcutaneous administration in patients requiring and not requiring dialysis. Clinical studies in patients with chronic kidney disease (CKD) have shown darbepoetin alfa to be equivalent to r-HuEPO in terms of increases in hemoglobin concentration, percentage of patients obtaining target hemoglobin, and average time to reach target hemoglobin concentration. Trials are currently ongoing in patients receiving cancer chemotherapy. The adverse event profile appears to be similar between the 2 agents.
CONCLUSIONS:
The equivalent efficacy and safety profile, as well as the longer half-life, may make darbepoetin alfa an attractive alternative to r-HuEPO in patients with CKD. Since these patients need to receive r-HuEPO 1–3 × weekly at the expense of increased healthcare utilization to improve their hemoglobin, agents such as darbepoetin alfa, with longer durations of action, may reduce healthcare expenses. In addition, enhanced patient compliance may be realized with once-weekly or once every-other-week administration.
PickettJLThebergeDCBrownWS. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis1999;33: 1122–30.
2.
JohansenK. Physical functioning and exercise capacity in patients on dialysis. Adv Renal Replace Ther1999;69: 141–8.
3.
BenzRLPressmanMRHovickETPetersonDD. A preliminary study of the effects of correction of anemia with recombinant erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEEPO Study). Am J Kidney Dis1999;34: 1089–95.
4.
MurphySTParfreyPS. The impact of anemia correction on cardiovascular disease in end-stage renal disease. Semin Nephrol2000;20: 350–5.
5.
StamatakisMKJoyMS. Updates in chronic renal failure and hemodialysis. In: CarterBL eds. Pharmacotherapy self assessment program. 3rd ed.. Kansas City: American College of Clinical Pharmacy, 1999: 1–48.
6.
LacombeCDa SilvaJLBrunevalPFournierJFWendlingFCasadevallNPeritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest1988;81: 620–3.
7.
KourySTBondurantMCKouryMJSemenzaGL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood1991;77: 2497–503.
8.
MorenoFSanz-GuajardoDManuelJLopez-GomezJMJofreRValderrabanoF. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol2000;11: 335–42.
9.
GlaspyJBukowskiRSteinbergDTaylorCTchekmedyianSVadhan-RajSImpact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol1997;15: 1218–34.
10.
US Renal Data System: USRDS 1998 annual data report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, April 1998.
11.
HenryDHBrooksBJCaseDCFishkinEJacobsonRKellerAMRecombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am1995;1: 252–60.
12.
LudwigHFritzELeitgebCPecherstorferMSamoniggHSchusterJ. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood1994;84: 1056–63.
13.
KoellerJM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy1998;18: 156–69.
14.
Package insert. Epogen (recombinant human erythropoietin). Thousand Oaks, CA: Amgen, November 14, 1996.
15.
NKF-DOQI clinical practice guidelines for anemia of chronic renal failure. National Kidney Foundation — Dialysis Outcomes Quality Initiative. Am J Kidney Dis1997;30(4) (suppl 3):S192–240.
16.
LinFKSuggsSLinCHBrowneJKSmallingREgrieJCCloning and expression of the human erythropoietin gene. Proc Natl Acad Sci1985;82: 7580–4.
17.
EgrieJCGrantJRGilliesDKAokiKHStricklandTW. The role of carbohydrate on the biological activity of EPO (abstract). Glycoconjugate J1993;10:263.
18.
EgrieJCDwyerELykosMHitzABrowneJK. Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (r-Hu-EPO) (abstract). Blood1997;90(10suppl 1):243.
19.
EgrieJCBrowneJK. Development and characterization of novel erythropoiesis stimulating-protein (NESP). Br J Cancer2001;84(suppl 1):3–10.
20.
MacdougallICGraySJElstonOBreenCJenkinsBBrowneJPharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol1999;10: 2392–5.
21.
LernerGRKaleASWaradyBAJabsKLBunchmanTEMaroniBJThe pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in pediatric patients with chronic renal failure (CRF) or end-stage renal disease (abstract). J Am Soc Nephrol2000;11:1479A.
22.
AteshkadiAJohnsonCAOxtonLLHammondTGBohenekWSZimmermanSW. Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis1993;21: 635–42.
23.
EvansJHCBrocklebankJTBowmerCJNgPC. Pharmacokinetics of recombinant human erythropoietin in children with renal failure. Nephrol Dial Transplant1991;6: 709–14.
24.
GlaspyJColowickAHeatheringtonA, NESP Oncology Study Group. Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half life (T1/2) in oncology patients (pts) (abstract)Proc ASCO2000;19:54A.
25.
HeatheringtonACSchullerJMercerAJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: Preliminary report. Br J Cancer2001:84(suppl 1):11–6.
26.
HeatheringtonARovettiRKotasekDGlaspyJColowickA. Predictability of pharmacokinetic properties of NESP administered once every 3 weeks in patients with nonmyeloid malignancies receiving cyclic chemotherapy (abstract). Proc ASCO2001;20:119A.
27.
AllonMKleinmanKWalczykMKaupkeCMaroniBJHeatheringtonAThe pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time- and dose-linear (abstract). J Am Soc Nephrol2000;11:1308A.
28.
MacdougallIC. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anemia (abstract). J Am Soc Nephrol1998;9: 258–9.
29.
CoyneDLingBNTotoRMcDermott-VitakADTrotmanMLJacksonL. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO) (abstract). J Am Soc Nephrol2000;11:3029A.
30.
VanrenterghemYBaranyPMannJ, European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week (abstract). J Am Soc Nephrol1999;10:1365A.
31.
LocatelliFOlivaresJWalkerRWilkieMJenkinsBDeweyCNovel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int2001;60: 741–7.
32.
SuranyiMWalkerRJacksonLFeasterJMcDermott-VitakA. Novel erythropoiesis stimulating protein (NESP) administered once every other week corrects anemia in patients with early chronic kidney disease (abstract). J Am Soc Nephrol2001;12:364.
33.
NissensonARSwanSKLindbergJSSorokaSDMcDermott-VitakADWangCNovel erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r-HuEPO when administered once weekly (abstract). J Am Soc Nephrol2000;11:1326A.
34.
GrafHLacombeJ-LBraunJda CostaGomes AA. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hgb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in ESRD patients (abstract). J Am Soc Nephrol2000;11:1317A.
35.
VanrenterghemYJadoulMForetMWalkerR. Novel erythropoiesis stimulating protein (NESP) administered once every 3 weeks by the intravenous or subcutaneous route maintains hemoglobin (Hgb) in dialysis patients (abstract). J Am Soc Nephrol2001;12:365A.
36.
BochicchioTCorrea-RotterRTrinidadRPTrevinoBAFeasterJHusainINovel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in dialysis patients in Mexico (abstract). J Am Soc Nephrol2001;12:352A.
37.
GlaspyJJadejaJSJusticeGKesslerJRischardsDSchwartzbergLA dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer2001;84(suppl 1):17–23.
38.
HedenusMHansenSDeweyCWatsonDColowickAOsterborgAA randomized, blinded, placebo-controlled, Phase II, dose-finding study of NESP in patients with lymphoproliferative malignancies (abstract). Proc ASCO2001;20:393A.
39.
SmithRMezaLTchekmedyianSChanDJaiyesimiIFleishmanAOpen-label, Phase I/II dose escalation study of NESP in patients with chronic anemia of cancer (abstract). Eur J Cancer2001;37(suppl 6):355.
40.
GlaspyJJadejaJJusticeGKesslerJRichardsDSchwartzbergLRandomized, active-controlled, Phase I/II, dose-escalation study of NESP administered weekly and every 2 weeks in patients with solid tumors (abstract). Proc ASCO2001;20:387A.
41.
PirkerRVansteenkisteJGateleyJYatesPColowickAMusilJ. A Phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer (abstract). Eur J Cancer2001;37(suppl 6):264.
42.
SmithREJaiyesimiIAMezaLATchekmedyianNSChanDGriffithHNovel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer2001;84(suppl 1):24–30.
43.
GlaspyJJadejaJJusticeGKesslerJRichardsDSchwartzbergL. Randomized, active-controlled, phase I/II, dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors (abstract). Eur J Cancer2001;37(suppl 6):353.
44.
Package insert. (Aranesp). Thousand Oaks, CA: Amgen, September 17, 2001.
JulianBAGastonRSBarkerCVKrystalGDiethelmAGCurtisJJ. Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis. Kidney Int1994;46: 1397–403.
47.
OnoyamaKSanaiTMotomuraKFujishimaM. Worsening of anemia by angiotensin-converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol1989;13(suppl 3):S27–30.
48.
Abu-AlfaAKCruzDPerazellaMAMahnensmithRLSimonDBiaMJ. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. Am J Kidney Dis2000;35: 1076–82.
CruzDNPerazellaMAAbu-AlfaAKMahnensmithRL. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?Am J Kidney Dis1996;28: 535–40.
51.
VereerstraetenAGastaldelloKGervyCVanherweghemJLTielemansC. High hematocrit in haemodialysis patients can be controlled by theophylline administration. Nephrol Dial Transplant1994;9: 189–91.
52.
LinACGoldwasserEBernardEMChapmanSW. Amphotericin B blunts erythropoietin response to anemia. J Infect Dis1990;161: 348–51.
53.
K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis2001;37(1suppl 1):S182–238.
54.
Drug topics red book. Montvale, NJ: Medical Economics Company, Aranesp. 2002:213.
55.
Procrit. 2002 Drug topics red book. Montvale, NJ: Medical Economics Company, 2002:506.
56.
Epogen. 2002 Drug topics red book: update 2000. Montvale, NJ: Medical Economics Company, 2002:328.
